Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196276 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL17923466 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL9431529 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL19287109 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL11575727 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL179941 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL2094913 | 1.00 | — | — | |
| SCHEMBL11251398 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL994389 | 0.97 | — | — | |
| SCHEMBL481638 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| US-8318638-B2 | Plant activator | SHISEIDO COMPANY, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120220462-A1 | INDUCING AGENT FOR PLANT ROOT | SHISEIDO COMPANY, LTD. | 2012-08-30 | — | — | US | disclosed |
| US-20110152101-A1 | Plant Activator | SHISEIDO COMPANY, LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| WO-2010039256-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152101-A1 | Plant Activator | DAGLA, OSBPL8, ACSL4 | TSHR 3765/4885FAAH 275/4885TRPV1 745/4885 |
| US-20120220462-A1 | INDUCING AGENT FOR PLANT ROOT | HMGCR, ACSL4, FASN | TSHR 2282/4885FAAH 136/4885TRPV1 4762/4885 |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | TSHR 2541/4885FAAH 189/4885TRPV1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.